Cargando…

Poxvirus immunotherapies in combination with immune checkpoint inhibitors synergize to eliminate tumors in a mouse tumor model

Detalles Bibliográficos
Autores principales:	Foy, Susan P, Rountree, Ryan B, Mandl, Stefaine J, Cote, Joseph, dela Cruz, Tracy, Gordon, Evan, Trent, Erica, Delcayre, Alain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991381/ http://dx.doi.org/10.1186/2051-1426-1-S1-P72

Ejemplares similares

Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells
por: Foy, Susan P., et al.
Publicado: (2016)

Poxvirus-based active immunotherapy synergizes with immune checkpoint inhibitors to cause tumor regression and extend survival in preclinical models of cancer
por: Foy, Susan P, et al.
Publicado: (2014)

Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy
por: Mandl, Stefanie J, et al.
Publicado: (2014)

Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice
por: Foy, Susan P., et al.
Publicado: (2016)

Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
por: Duan, Xiaopin, et al.
Publicado: (2019)

Targeting tumor-associated macrophages to synergize tumor immunotherapy
por: Xiang, Xiaonan, et al.
Publicado: (2021)

Immunotherapy with MVA-BN(®)-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells
por: Mandl, Stefanie J., et al.
Publicado: (2011)

Immune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy
por: Dörrie, Jan
Publicado: (2016)

Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy
por: Yao, Yongrong, et al.
Publicado: (2022)

Intermittent dietary methionine deprivation facilitates tumoral ferroptosis and synergizes with checkpoint blockade
por: Xue, Ying, et al.
Publicado: (2023)

Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy
por: Vähä-Koskela, Markus, et al.
Publicado: (2015)

Recombinant Poxvirus and the Tumor Microenvironment: Oncolysis, Immune Regulation and Immunization
por: Sharp, Daniel W., et al.
Publicado: (2016)

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy
por: Xu, Shumin, et al.
Publicado: (2023)

Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection
por: Zamarin, Dmitriy, et al.
Publicado: (2013)

β-Catenin inhibition shapes tumor immunity and synergizes with immunotherapy in colorectal cancer
por: Wang, Caihong, et al.
Publicado: (2020)

Targeting phosphatidylserine synergizes with immune checkpoint blockade by inducing de novo tumor specific immunity
por: Huang, Xianming, et al.
Publicado: (2015)

Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
por: Draganov, Dobrin, et al.
Publicado: (2021)

Poxvirus tropism
por: McFadden, Grant
Publicado: (2005)

Poxvirus Recombination
por: Evans, David Hugh
Publicado: (2022)

Zoonotic poxviruses()
por: Essbauer, Sandra, et al.
Publicado: (2010)

Immune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastoma
por: Gershan, Jill A., et al.
Publicado: (2015)

Polyoxazoline‐Based Nanovaccine Synergizes with Tumor‐Associated Macrophage Targeting and Anti‐PD‐1 Immunotherapy against Solid Tumors
por: Matos, Ana I., et al.
Publicado: (2023)

PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models
por: Yamazaki, Takahiro, et al.
Publicado: (2020)

The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy
por: Patel, Mira A., et al.
Publicado: (2014)

Macrophage polarization synergizes with oxaliplatin in lung cancer immunotherapy via enhanced tumor cell phagocytosis
por: Li, Fei, et al.
Publicado: (2021)

Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy
por: Xie, Guozhu, et al.
Publicado: (2018)

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
por: Arora, Sanjeevani, et al.
Publicado: (2019)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
por: Naimi, Adel, et al.
Publicado: (2022)

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells
Publicado: (1982)

The Evolution of Poxvirus Vaccines
por: Sánchez-Sampedro, Lucas, et al.
Publicado: (2015)

Decoding poxvirus genome
por: Yang, Zhilong, et al.
Publicado: (2015)

Immunotherapy Strategies for Gastrointestinal Stromal Tumor
por: Arshad, Junaid, et al.
Publicado: (2021)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
por: Duan, Jingjing, et al.
Publicado: (2018)

Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors
por: Franzese, Ornella, et al.
Publicado: (2017)

Nanobodies targeting immune checkpoint molecules for tumor immunotherapy and immunoimaging (Review)
por: Yu, Sheng, et al.
Publicado: (2021)

Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors
por: Tateo, Valentina, et al.
Publicado: (2020)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Checkpoint inhibitors synergize with therapeutic platforms, ZVex™ and GLAAS™ by enhancing lentiviral vector-induced tumor-specific immunity and adjuvant-mediated anti-tumor efficacy
por: Albershardt, Tina C, et al.
Publicado: (2015)

Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models
por: Papaevangelou, Efthymia, et al.
Publicado: (2023)

A safer poxvirus vaccine
por: Bashyam, Hema
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_vb0kh6suhqcm1jvsvcos9d92cf